Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study to evaluate the safety and efficacy of IDX719 in combinations with simeprevir and/or TMC647055/ritonavir with or without ribavirin for 12 weeks in subjects with chronic hepatitis C infection

Next Previous
X
Search
Trial Profile

A randomized study to evaluate the safety and efficacy of IDX719 in combinations with simeprevir and/or TMC647055/ritonavir with or without ribavirin for 12 weeks in subjects with chronic hepatitis C infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Samatasvir (Primary) ; Simeprevir (Primary) ; TMC 647055 (Primary) ; Ribavirin; Ritonavir
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HELIX-1
  • Sponsors Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 22 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 02 Mar 2015 Study focus of therapeutic use was added to the protocol; in treatment table genotypes 1a, 1b and 4 were included and treatment arms changed from 3 to 8; primary endpoint time frame changed to 95, 66 and 16 weeks.
    • 02 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top